Previous close | 9.31 |
Open | 9.34 |
Bid | 9.42 x 200 |
Ask | 9.48 x 200 |
Day's range | 9.15 - 9.48 |
52-week range | 4.22 - 10.00 |
Volume | |
Avg. volume | 843,613 |
Market cap | 671.396M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | 9.94 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 25 Mar 2024 |
1y target est | N/A |
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at www.siga.com under the 'Even
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key c
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving